BioAge Labs (NASDAQ:BIOA) Now Covered by Oppenheimer

Oppenheimer started coverage on shares of BioAge Labs (NASDAQ:BIOA) in a research note released on Wednesday, MarketBeat.com reports. The firm issued an outperform rating and a $60.00 price target on the stock.

Several other research firms have also recently weighed in on BIOA. Wall Street Zen upgraded BioAge Labs from a “sell” rating to a “hold” rating in a research note on Tuesday, February 3rd. Morgan Stanley set a $23.00 price objective on shares of BioAge Labs in a research report on Wednesday, February 4th. Piper Sandler began coverage on shares of BioAge Labs in a research report on Tuesday, January 27th. They issued an “overweight” rating on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of BioAge Labs in a research report on Tuesday, January 27th. Finally, Citigroup upped their price objective on shares of BioAge Labs from $10.00 to $15.00 and gave the company a “buy” rating in a research note on Wednesday, October 29th. Three investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $32.67.

BioAge Labs Price Performance

NASDAQ:BIOA opened at $22.14 on Wednesday. The business’s fifty day moving average price is $17.92 and its 200 day moving average price is $10.70. The firm has a market capitalization of $793.72 million, a PE ratio of -14.57 and a beta of 1.42. BioAge Labs has a 12 month low of $2.88 and a 12 month high of $24.00.

Insider Buying and Selling

In related news, CFO Dov A. Md Goldstein sold 27,000 shares of the stock in a transaction dated Tuesday, January 13th. The shares were sold at an average price of $19.70, for a total transaction of $531,900.00. Following the completion of the transaction, the chief financial officer directly owned 22,408 shares of the company’s stock, valued at $441,437.60. This represents a 54.65% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Kristen Fortney sold 233,107 shares of the firm’s stock in a transaction dated Tuesday, January 13th. The shares were sold at an average price of $18.12, for a total transaction of $4,223,898.84. Following the completion of the sale, the chief executive officer owned 976,949 shares of the company’s stock, valued at approximately $17,702,315.88. The trade was a 19.26% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 354,437 shares of company stock valued at $5,813,228 over the last three months. 20.82% of the stock is currently owned by company insiders.

Institutional Trading of BioAge Labs

Several hedge funds have recently modified their holdings of BIOA. Police & Firemen s Retirement System of New Jersey acquired a new position in BioAge Labs during the second quarter worth $27,000. Russell Investments Group Ltd. acquired a new position in shares of BioAge Labs during the 3rd quarter worth $27,000. CWM LLC grew its stake in shares of BioAge Labs by 39.9% during the 4th quarter. CWM LLC now owns 3,693 shares of the company’s stock worth $49,000 after purchasing an additional 1,053 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of BioAge Labs by 85.6% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,955 shares of the company’s stock valued at $54,000 after purchasing an additional 5,976 shares during the period. Finally, Intech Investment Management LLC acquired a new stake in shares of BioAge Labs in the second quarter valued at about $60,000.

BioAge Labs Company Profile

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.